Is Oculis Holding AG (OCS) Overvalued?
We dive into why Oculis Holding AG (OCS) could be considered overvalued on 2026-08-07, based on AAII’s Value Score and Grade.Tudor Pop
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company’s lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023. The company was founded in 2017 and is based in Zug, Switzerland.
Commentary & Analysis
Why Oculis Holding AG’s (OCS) Stock Is Up 5.39%
As of Monday, August 03, Oculis Holding AG’s OCS share price has surged by 5.39%, which has investors questioning if this is right time to sell.Michael Rose
Why Oculis Holding AG’s (OCS) Stock Is Down 5.58%
As of Thursday, July 16, Oculis Holding AG’s OCS share price has dipped by 5.58%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Oculis Holding AG’s (OCS) Stock Is Up 9.43%
As of Tuesday, June 09, Oculis Holding AG’s OCS share price has surged by 9.43%, which has investors questioning if this is right time to sell.Michael Rose
Why Oculis Holding AG’s (OCS) Stock Is Down 9.06%
As of Thursday, June 04, Oculis Holding AG’s OCS share price has dipped by 9.06%, which has investors questioning if this is right time to buy.Michael Rose
Financial Summary
| Share Statistics | OCS | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $811.2 | $618.0 | 42% |
|
| Shares Out (Mil) | 75.8 | 44.8 | 57% |
|
| Institutional Ownership | 88.7% | 85.3% | 57% |
|
| Float (Mil) | 52.4 | 47.4 | 48% |
|
| Beta | na | 0.70 | na |
|
| Avg Daily Volume (000s) | 218 | 390 | 45% |
|
| Price Change (52-week) |
(26.8%) | 68.6% | 25% |
|
| Growth | OCS | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 6.4% | 6.7% | 43% |
|
| Net Income (5yr) | (49.3%) | (1.6%) | 7% |
|
| EPS (5yr) | 18.2% | 14.9% | 65 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 18.8% | (14.9%) | 78% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 8 | 7 | 7 | |
| Current EPS | ($0.499) | ($1.955) | ($2.061) | |
| Month Ago EPS | ($0.522) | ($2.245) | ($2.049) | |
| # Rev Up | 0 | 1 | 0 | |
| # Rev Down | 1 | 0 | 1 | |
| Three Months Ago EPS | ($0.562) | ($2.241) | ($2.052) | |
| Year/Year Chg | 148.3% | (18.2%) | (32.4%) | |
| Financials | OCS | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $2 | $291 | 3% |
|
| Net Income (TTM) (Mil) | ($98) | ($11) | 11% |
|
| EPS (TTM) | ($1.715) | ($0.700) | 16% |
|
| Operating Cash Flow (TTM) (Mil) | ($81) | ($6) | 7% |
|
| Net Cash Flow (TTM) (Mil) | ($3) | $5 | 36% |
|
| Long-Term Debt (Q1) (Mil) | $2 | $6 | 20% |
|
| Enterprise Value (Q1) (Mil) | na | $450 | na |
|
| Valuation | OCS | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.99 | 2.78 | 64% |
|
| P/E | na | 17.4 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | OCS | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.0% | na |
|
| Net Margin | na | (2.3%) | na |
|
| ROA | (36.4%) | (22.4%) | 15% |
|
| ROE | (43.4%) | (20.2%) | 17% |
|
| Liabilities to Assets | 12.4% | 32.2% | 7% |
|
| F-Score | 4 | 3 | 34% |
|
Oculis Holding AG did not pass any screens on 8/20/2026.
